Business Wire

TECNOTREE

22.12.2022 11:36:36 CET | Business Wire | Press release

Share
Tecnotree Announces Simultaneous Production Launch of its Digital Stack for 5 Provider Groups, across Europe, Middle East and Africa for 100 million Subscribers

Tecnotree, a global digital platform and services leader for 5G and cloud-native technology, announced the simultaneous rollout of their digital BSS solutions for telecom service providers across Middle East, Africa, and Europe with a combined total of over 100 million subscribers. The rollout was part of the customers’ large-scale digital BSS transformation with Tecnotree Digital Suite for enterprise-B2B and consumer-B2C businesses for some of the largest operator groups like MTN, STC, Zain Group, Omantel and a Provider in Western Europe.

Tecnotree’s 5G-Ready Digital suite implementation provides customers with a differentiated product and service offerings built on TMF Open API, ODA compliant Microservices driven architecture with cutting edge technologies to digitally enable our customers to create a market differentiator and provide a new age experience to the end subscribers. The program involves transforming the customers’ legacy business processes, products, services, and customer experience with a consultative and advisory-led approach to provide a refreshing new-age digital experience. The full digital stack deployment includes Lead & Prospect, Customer Life Cycle Management, Catalog driven Order Management, Resource & Inventory Management, Loyalty Management, Service Provisioning, and Mediation, Convergent and Wholesale Billing, Business Operations Dashboard, and Call Completion systems providing end-to-end digital Customer Experience.

Tecnotree’s 5G-ready digital BSS suite with AI/ML capabilities comprises a full range of business processes with a product catalogue driven customer engagement of digital journeys and microservices, that support customer lifecycle and revenue management. Tecnotree has an agile and open-source Digital BSS Stack which is cloud-native, Open Digital Architecture (ODA) compliant, and platinum certified by TM Forum for real-world Open API implementation standards.

“We are excited to announce Tecnotree’s many successful go-lives across the continents. With these achievements, Tecnotree is taking important steps towards expanding to a wider global market. It demonstrates our scalability for swift deployments and the capability to deliver customer expectations. Tecnotree with its award-winning products has successfully transformed several legacy systems, meeting the rapidly changing consumer demands with innovative new offerings, preparing them for the new monetization opportunities presented by 5G and IoT,” said Padma Ravichander, CEO of Tecnotree Corporation.

“We are proud to partner with global Telecom Service Providers to roll out a Differentiated Digital Experience to Business, IT, Operations, and end subscribers through a Collaborative Consultative and Business Value driven Agile delivery using our advanced Microservices Accelerator platform and automation suites to enable faster delivery and parallel launches," said Ramaseshan Subramanian, Vice President & Head of Global Delivery & Operations, Tecnotree. "Our multi-functional delivery teams are trained in the latest automation technologies to provide the Best-in-Class delivery in an agile customer-success driven approach and ensure zero-touch delivery across the continents."

About Tecnotree

Tecnotree is a 5G-ready digital Business Support System (BSS) player, with AI/ML capabilities and multi-cloud extensibility. Tecnotree is among the first companies in the world to be Platinum Certified by TM Forum Open API standards, and our agile and open-source Digital BSS Stack comprises the full range (order-to-cash) of business processes and subscription management for telecom and other digital services industries creating opportunities beyond connectivity. Tecnotree also provides Fintech and B2B2X multi-experience digital marketplace to its subscriber base through the Tecnotree Moments platform to empower digitally connected communities across gaming, health, education, OTT, and other vertical ecosystems. Tecnotree is listed on Helsinki Nasdaq (TEM1V).

For more information, please visit www.tecnotree.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221222005173/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release

In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye